Abstract
Intravascular large B-cell lymphoma (IVLBCL) is one of the rarest B-cell non-Hodgkin lymphomas (NHL), with an aggressive clinical behavior and a poor prognosis; in fact, its treatment is still an unmet clinical need, with a 3-year overall survival (OS) rate of 60% to 81%, and a central nervous system relapse rate of 25%. It usually presents as a widespread disease at diagnosis, with multi-organ involvement. Previously considered as a diffuse large B-cell lymphoma variant, it now represents a different extranodal large B-cell lymphoma entity in the last WHO Classification of tumors of hematopoietic and lymphoid tissues. We hereby describe the case of an 84-year-old Italian woman with an IVLBCL, cutaneous variant, who suffered from early relapse after R-COMP chemotherapy regimen, and was therefore treated with a palliative metronomic chemotherapy. Interestingly, neoplastic cells showed CD30 expression at relapse. CD30 positivity has never been reported in this disease so far, and its expression is known to be involved in NF-kB activation. CD30 expression may be further studied as for prognostic and therapeutic significance; in fact, new therapeutic strategies, such as antibody-drug conjugate targeting CD30, are now available.
| Original language | English |
|---|---|
| Pages (from-to) | 447-451 |
| Journal | Journal of Cutaneous Pathology |
| Volume | 46 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - Jan 1 2019 |
Fingerprint
ASJC Scopus subject areas
- Pathology and Forensic Medicine
- Histology
- Dermatology
Cite this
CD30 expression in a case of intravascular large B-cell lymphoma, cutaneous variant. / Provasi, Matteo; Filippo, Bagnoli; Daniele, Fanoni; Alberti Violetti, Silvia; Dario, Tomasini; Berti, Emilio.
In: Journal of Cutaneous Pathology, Vol. 46, No. 6, 01.01.2019, p. 447-451.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - CD30 expression in a case of intravascular large B-cell lymphoma, cutaneous variant
AU - Provasi, Matteo
AU - Filippo, Bagnoli
AU - Daniele, Fanoni
AU - Alberti Violetti, Silvia
AU - Dario, Tomasini
AU - Berti, Emilio
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Intravascular large B-cell lymphoma (IVLBCL) is one of the rarest B-cell non-Hodgkin lymphomas (NHL), with an aggressive clinical behavior and a poor prognosis; in fact, its treatment is still an unmet clinical need, with a 3-year overall survival (OS) rate of 60% to 81%, and a central nervous system relapse rate of 25%. It usually presents as a widespread disease at diagnosis, with multi-organ involvement. Previously considered as a diffuse large B-cell lymphoma variant, it now represents a different extranodal large B-cell lymphoma entity in the last WHO Classification of tumors of hematopoietic and lymphoid tissues. We hereby describe the case of an 84-year-old Italian woman with an IVLBCL, cutaneous variant, who suffered from early relapse after R-COMP chemotherapy regimen, and was therefore treated with a palliative metronomic chemotherapy. Interestingly, neoplastic cells showed CD30 expression at relapse. CD30 positivity has never been reported in this disease so far, and its expression is known to be involved in NF-kB activation. CD30 expression may be further studied as for prognostic and therapeutic significance; in fact, new therapeutic strategies, such as antibody-drug conjugate targeting CD30, are now available.
AB - Intravascular large B-cell lymphoma (IVLBCL) is one of the rarest B-cell non-Hodgkin lymphomas (NHL), with an aggressive clinical behavior and a poor prognosis; in fact, its treatment is still an unmet clinical need, with a 3-year overall survival (OS) rate of 60% to 81%, and a central nervous system relapse rate of 25%. It usually presents as a widespread disease at diagnosis, with multi-organ involvement. Previously considered as a diffuse large B-cell lymphoma variant, it now represents a different extranodal large B-cell lymphoma entity in the last WHO Classification of tumors of hematopoietic and lymphoid tissues. We hereby describe the case of an 84-year-old Italian woman with an IVLBCL, cutaneous variant, who suffered from early relapse after R-COMP chemotherapy regimen, and was therefore treated with a palliative metronomic chemotherapy. Interestingly, neoplastic cells showed CD30 expression at relapse. CD30 positivity has never been reported in this disease so far, and its expression is known to be involved in NF-kB activation. CD30 expression may be further studied as for prognostic and therapeutic significance; in fact, new therapeutic strategies, such as antibody-drug conjugate targeting CD30, are now available.
UR - http://www.scopus.com/inward/record.url?scp=85063892093&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85063892093&partnerID=8YFLogxK
U2 - 10.1111/cup.13446
DO - 10.1111/cup.13446
M3 - Article
AN - SCOPUS:85063892093
VL - 46
SP - 447
EP - 451
JO - Journal of Cutaneous Pathology
JF - Journal of Cutaneous Pathology
SN - 0303-6987
IS - 6
ER -